21 years of historical data (2005–2025) · Healthcare · Medical - Instruments & Supplies
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
InfuSystem Holdings, Inc. trades at 32.7x earnings, 99% below its 5-year average of 2300.6x, sitting at the 67th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.2x, the stock trades at a premium of 48%. On a free-cash-flow basis, the stock trades at 8.6x P/FCF, 98% below the 5-year average of 506.6x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $206M | $189M | $183M | $228M | $187M | $376M | $408M | $178M | $74M | $52M | $58M |
| Enterprise Value | $206M | $189M | $211M | $263M | $224M | $412M | $441M | $218M | $103M | $78M | $92M |
| P/E Ratio → | 32.71 | 28.94 | 76.82 | 263.50 | 10850.00 | 283.83 | 23.48 | 130.63 | — | — | — |
| P/S Ratio | 1.44 | 1.32 | 1.36 | 1.81 | 1.70 | 3.67 | 4.19 | 2.19 | 1.10 | 0.74 | 0.82 |
| P/B Ratio | 3.73 | 3.30 | 3.19 | 4.36 | 3.90 | 7.78 | 10.01 | 7.96 | 3.60 | 1.69 | 1.14 |
| P/FCF | 8.64 | 7.94 | 69.85 | 2152.36 | 76.62 | 226.21 | 121.17 | — | 23.86 | 13.11 | — |
| P/OCF | 8.44 | 7.75 | 8.97 | 20.33 | 10.68 | 20.50 | 20.11 | 12.81 | 6.47 | 6.90 | 7.29 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
InfuSystem Holdings, Inc.'s enterprise value stands at 8.2x EBITDA, 44% below its 5-year average of 14.6x. The Healthcare sector median is 14.1x, placing the stock at a 42% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.32 | 1.57 | 2.09 | 2.04 | 4.02 | 4.53 | 2.69 | 1.54 | 1.10 | 1.30 |
| EV / EBITDA | 8.18 | 7.52 | 10.90 | 15.84 | 14.90 | 23.62 | 19.29 | 13.75 | 8.80 | 8.98 | 7.82 |
| EV / EBIT | 17.31 | 15.89 | 28.06 | 65.36 | 146.07 | 156.45 | 50.11 | 63.63 | 272.85 | — | 93.55 |
| EV / FCF | — | 7.95 | 80.47 | 2479.42 | 91.68 | 248.24 | 130.98 | — | 33.40 | 19.63 | — |
Margins and return-on-capital ratios measuring operating efficiency
InfuSystem Holdings, Inc. earns an operating margin of 8.3%. Operating margins have expanded from 3.3% to 8.3% over the past 3 years, signaling improving operational efficiency. ROE of 25.5% indicates solid capital efficiency. ROIC of 12.5% represents solid returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.0% | 56.0% | 52.2% | 50.2% | 55.1% | 57.2% | 60.3% | 57.8% | 58.1% | 61.0% | 63.5% |
| Operating Margin | 8.3% | 8.3% | 5.1% | 3.3% | 1.5% | 2.8% | 9.1% | 4.3% | 0.6% | -5.4% | 1.4% |
| Net Profit Margin | 10.2% | 10.2% | 1.7% | 0.7% | 0.0% | 1.4% | 17.8% | 1.7% | -1.6% | -29.1% | -0.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 25.5% | 25.5% | 4.3% | 1.7% | 0.0% | 3.2% | 54.9% | 6.4% | -4.3% | -50.7% | -0.4% |
| ROA | 14.3% | 14.3% | 2.3% | 0.9% | 0.0% | 1.5% | 19.7% | 1.9% | -1.6% | -25.1% | -0.2% |
| ROIC | 12.5% | 12.5% | 6.0% | 3.6% | 1.5% | 2.7% | 9.7% | 4.7% | 0.6% | -4.0% | 0.9% |
| ROCE | 14.3% | 14.3% | 8.0% | 4.8% | 2.0% | 3.6% | 13.4% | 6.6% | 0.8% | -5.6% | 1.2% |
Solvency and debt-coverage ratios — lower is generally safer
InfuSystem Holdings, Inc. carries a Debt/EBITDA ratio of 0.1x, which is very conservative (96% below the sector average of 3.1x). Net debt stands at $241000 ($3M total debt minus $3M cash). Interest coverage of 9.2x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | 0.49 | 0.67 | 0.77 | 0.76 | 1.05 | 1.93 | 1.65 | 0.95 | 0.74 |
| Debt / EBITDA | 0.14 | 0.14 | 1.47 | 2.10 | 2.46 | 2.11 | 1.87 | 2.71 | 2.88 | 3.38 | 3.19 |
| Net Debt / Equity | — | 0.00 | 0.48 | 0.66 | 0.77 | 0.76 | 0.81 | 1.81 | 1.44 | 0.84 | 0.67 |
| Net Debt / EBITDA | 0.01 | 0.01 | 1.44 | 2.09 | 2.45 | 2.10 | 1.44 | 2.54 | 2.51 | 2.98 | 2.90 |
| Debt / FCF | — | 0.01 | 10.62 | 327.07 | 15.06 | 22.04 | 9.81 | — | 9.54 | 6.51 | — |
| Interest Coverage | 9.18 | 9.18 | 3.88 | 1.88 | 1.18 | 2.05 | 7.03 | 1.85 | 0.29 | -2.86 | 0.72 |
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.80x means InfuSystem Holdings, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 1.95x to 1.80x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.80 | 1.80 | 1.82 | 1.95 | 1.71 | 1.71 | 1.29 | 0.88 | 1.19 | 1.42 | 1.26 |
| Quick Ratio | 1.53 | 1.53 | 1.45 | 1.54 | 1.38 | 1.41 | 1.16 | 0.75 | 1.03 | 1.27 | 1.13 |
| Cash Ratio | 0.16 | 0.16 | 0.03 | 0.01 | 0.01 | 0.01 | 0.42 | 0.12 | 0.29 | 0.28 | 0.21 |
| Asset Turnover | — | 1.43 | 1.30 | 1.22 | 1.11 | 1.05 | 1.00 | 1.02 | 1.05 | 1.03 | 0.73 |
| Inventory Turnover | 11.71 | 11.71 | 9.87 | 9.79 | 10.24 | 11.13 | 12.87 | 11.81 | 12.48 | 15.71 | 11.89 |
| Days Sales Outstanding | — | 58.28 | 57.26 | 57.54 | 56.02 | 54.92 | 55.17 | 54.43 | 52.15 | 57.95 | 59.96 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
InfuSystem Holdings, Inc. returns 5.3% to shareholders annually primarily through share buybacks. The earnings yield of 3.1% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.1% | 3.5% | 1.3% | 0.4% | 0.0% | 0.4% | 4.3% | 0.8% | — | — | — |
| FCF Yield | 11.6% | 12.6% | 1.4% | 0.0% | 1.3% | 0.4% | 0.8% | — | 4.2% | 7.6% | — |
| Buyback Yield | 5.3% | 5.8% | 1.1% | 0.6% | 3.6% | 0.5% | 0.4% | 0.4% | 14.2% | 0.1% | 0.1% |
| Total Shareholder Yield | 5.3% | 5.8% | 1.1% | 0.6% | 3.6% | 0.5% | 0.4% | 0.4% | 14.2% | 0.1% | 0.1% |
| Shares Outstanding | — | $21M | $22M | $22M | $22M | $22M | $22M | $21M | $21M | $23M | $23M |
Compare INFU with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| $206M | 32.7 | 8.2 | 8.6 | 56.0% | 8.3% | 25.5% | 12.5% | 0.1 | |
| $272M | -21.9 | 20.2 | 25.2 | 0.2% | 11.4% | -6.3% | 1.3% | 13.6 | |
| $2B | 27.2 | 22.1 | 11.4 | 13.0% | 2.6% | 11.7% | 9.0% | 0.4 | |
| $121M | 24.0 | 6.4 | 6.5 | 67.3% | 10.7% | 4.2% | 7.1% | 0.3 | |
| $7B | -28.3 | — | — | 70.0% | -1135.6% | -53.4% | -46.2% | — | |
| $2B | 987.8 | 23.8 | 22.9 | 42.5% | 0.4% | 0.2% | 0.3% | 2.4 | |
| $544M | 11.4 | 5.1 | 7.5 | 82.6% | 15.3% | 21.6% | 42.3% | 0.3 | |
| $2B | -13.5 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — | |
| $1B | -16.9 | — | 26.8 | 49.8% | -8.8% | -8.5% | -5.4% | — | |
| $585M | -294.3 | 18.1 | 13.8 | 62.6% | 6.8% | -1.3% | 3.7% | 4.4 | |
| $9B | -9.7 | 25.0 | 27.1 | 30.1% | -2.7% | -14.6% | -1.4% | 14.9 | |
| Healthcare Median | — | 22.2 | 14.1 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Includes 30+ ratios · 21 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationSide-by-side business, growth, and profitability comparison vs BRT Apartments Corp..
Start ComparisonQuick answers to the most common questions about buying INFU stock.
InfuSystem Holdings, Inc.'s current P/E ratio is 32.7x. The historical average is 42.9x. This places it at the 67th percentile of its historical range.
InfuSystem Holdings, Inc.'s current EV/EBITDA is 8.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 10.3x.
InfuSystem Holdings, Inc.'s return on equity (ROE) is 25.5%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -1.6%.
Based on historical data, InfuSystem Holdings, Inc. is trading at a P/E of 32.7x. This is at the 67th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
InfuSystem Holdings, Inc. has 56.0% gross margin and 8.3% operating margin.
InfuSystem Holdings, Inc.'s Debt/EBITDA ratio is 0.1x, indicating low leverage. A ratio below 2x is generally considered financially healthy.